Sangamo Therapeutics

Type| Public

Traded as

| NASDAQ: SGMO
Russell 2000 Index component
Industry| Biotechnology
Founded| 1995
Headquarters|

Brisbane, California, US

Key people

| Sandy Macrae (CEO)

Revenue|  $111.3 million[1] (2022)

Operating income

|  -$201.281 million[1] (2022)

Net income

|  $192.3 million[1] (2022)
Total assets|  $562.5 million[1] (2022)
Total equity|  $294.958 million[1] (2022)

Number of employees

| 354
Website| sangamo.com
Footnotes / references
[1]
President and CEO Sandy Macrae in 2018

Sangamo Therapeutics, Inc. (formerly Sangamo Biosciences, Inc.) is an American biotechnology company based in Brisbane, California, that develops cell and gene therapies for severe genetic diseases.[2]

## Contents

* 1 History
* 2 Research
* 3 Clinical trials
* 4 See also
* 5 References
* 6 External links

## History

The company was founded in 1995 in Richmond, California.[3] It was originally known as Sangamo Biosciences, Inc. before changing names in 2017. In September 2018, it had 182 employees.[3] Sandy Macrae is the president.[4] In 2018, Edward Rebar became the senior vice president and chief technology officer of Sangamo.[5]

Sangamo Therapeutics' Sangamo name and, for a brief time, its logo, were taken from the earlier Sangamo Electric Company, founded as an offshoot of the Illinois Watch Company in January 1899, the name coming from the nearby Sangamon River.[6][7] The modern Sangamo's founder, Edward Oliver Lanphier II, is the great-grandson of one of Sangamo Electric's founders, Robert Carr Lanphier Sr.

## Research

Sangamo's clinical development programs have emerged from proprietary zinc finger and serine integrase gene editing technologies that the company has developed, coupled with its proprietary adeno-associated virus (AAV)-based delivery platform.[8][9] The company's clinical pipeline includes investigational treatments for haemophilia A; lysosomal storage diseases including Fabry disease, mucopolysaccharidosis type I (Hurler Syndrome), and mucopolysaccharidosis type II (Hunter Syndrome); and neurological disorders including small fiber neuropathy (SFN) and prion disease.[10]

The FDA granted Sangamo fast track designation for SB-525, a gene therapy candidate for haemophilia A. In its partnership with Pfizer in 2017,[11] Sangamo uses Bioverativ in hemoglobinopathies such as beta thalassemia and sickle cell disease.[2]

In February 2019, medical scientists, working with Sangamo Therapeutics, announced the first ever "in body" human gene editing therapy to permanently alter DNA \- in a patient with Hunter syndrome.[12] As of February 2019[update] clinical trials by Sangamo involving gene editing using zinc finger nuclease were ongoing.[13]

## Clinical trials

Sangamo's programs are a mix of wholly owned and partnered; major partners include Pfizer, Biogen, Sanofi, Takeda, and Kite (a Gilead company).[14][2][15][16]

As of 2020 Sangamo had the following clinical trials underway in the US:

* Phase 1/2 Thales study in beta thalassemia[17]
* Phase 1/2 STAAR study in Fabry disease[18]
* Phase 1/2 PRECIZN-1 study in sickle cell disease[19]
* Phase 1/2 CHAMPIONS study in MPS II[20]
* Phase 1/2 EMPOWERS study in MPS I[21]
* Phase 1/2 Alta study in hemophilia A[22]
* Phase 1 FIXTENDZ study in hemophilia B[23]

In February 2023, Sangamo Therapeutics announced that it would stop the late-stage development for the Phase 1/2 PRECIZN-1 study of BIVV003 its sickle cell drug.[24]

## See also

* Alan Wolffe
* Edward Rebar

## References

1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results". Sangamo. 22 February 2023. https://investor.sangamo.com/news-releases/news-release-details/sangamo-therapeutics-reports-recent-business-highlights-and-5.
2. ↑ 2.0 2.1 2.2 McConaghie, Andrew (2017-05-17). "Sangamo and new gene therapy partner Pfizer lifted by FDA fast track" (in en-GB). Pharmaphorum. https://pharmaphorum.com/news/sangamo-new-gene-therapy-partner-pfizer-lifted-fda-fast-track/.
3. ↑ 3.0 3.1 "Sangamo Therapeutics Inc. (SGMO) Moves Higher on Volume Spike for September 04" (in en-US). Equities. 2018-09-08. https://www.equities.com/news/sangamo-therapeutics-inc-sgmo-moves-higher-on-volume-spike-for-september-04.
4. ↑ Ledford, Heidi (2018-09-05). "First test of in-body gene editing shows promise" (in EN). Nature. doi:10.1038/d41586-018-06195-6. ISSN 0028-0836. http://www.nature.com/articles/d41586-018-06195-6.
5. ↑ "Sangamo Therapeutics appoints Edward Rebar as senior vice president" (in en). Richmond, California. 2018-07-16. http://www.poandpo.com/who-is-promoted/sangamo-therapeutics-appoints-edward-rebar-as-senior-vice-president--1672018988/.
6. ↑ "Sangamo: A History of Fifty Years". https://ia801307.us.archive.org/18/items/sangamohistoryof00lanp/sangamohistoryof00lanp_bw.pdf.
7. ↑ "The History of Sangamo Electric Company". http://www.sangamoclocks.com/history.
8. ↑ "Sangamo has its finger on the next evolution of gene editing". https://www.pharmavoice.com/news/sangamo-sandy-mcrae-gene-editing-zinc-finger/621283/.
9. ↑ Renauer, Cory (2018-09-06). "Sangamo's Zinc Fingers Fail Again. Time to Walk Away?" (in en). The Motley Fool. https://www.fool.com/investing/2018/09/06/sangamos-zinc-fingers-fail-again-time-to-walk-away.aspx.
10. ↑ "Programs". https://www.sangamo.com/programs/.
11. ↑ "SANGAMO THERAPEUTICS AND PFIZER ANNOUNCE COLLABORATION FOR HEMOPHILIA A GENE THERAPY | Pfizer". https://www.pfizer.com/news/press-release/press-release-detail/sangamo_therapeutics_and_pfizer_announce_collaboration_for_hemophilia_a_gene_therapy.
12. ↑ Marchione, Marilyn (7 February 2019). "Tests suggest scientists achieved 1st 'in body' gene editing". AP News. https://www.apnews.com/d728f86d70d94ce68dd4fedffe58d03f.
13. ↑ Staff (2 February 2019). "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II". U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT03041324.
14. ↑ "SGMO.OQ - Sangamo Therapeutics Inc Profile | Reuters" (in en). https://www.reuters.com/companies/SGMO.OQ.
15. ↑ "Sangamo shares jump on Pfizer, Sanofi (and its own) gene, cell therapy updates" (in en). https://www.fiercebiotech.com/biotech/sangamo-shares-jump-pfizer-sanofi-and-its-own-gene-and-cell-therapy-updates.
16. ↑ "Exciting new Huntingtin lowering tool described - HDBuzz - Huntington's disease research news.". https://en.hdbuzz.net/275.
17. ↑ "A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT03432364.
18. ↑ "Dose-Ranging Study of ST-920, a rAAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT04046224.
19. ↑ "A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT03653247.
20. ↑ "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT03041324.
21. ↑ "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT02702115.
22. ↑ "Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT03061201.
23. ↑ "Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT02695160.
24. ↑ "Sangamo shelves sickle cell therapy, joining rivals forced to rethink development plans" (in en). Fierce Biotech. 2023-02-23. https://www.fiercebiotech.com/biotech/sangamo-shelves-sickle-cell-therapy-joining-rivals-forced-rethink-development-plans-disease.

## External links

* No URL found. Please specify a URL here or add one to Wikidata.
* Business data for Sangamo Therapeutics:

* Google Finance
* Yahoo! Finance
* Reuters
* SEC filings

[ ⚑ ]  37°40′36″N 122°23′03″W﻿ / ﻿37.67669°N 122.38421°W﻿ / 37.67669; -122.38421

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Sangamo Therapeutics. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Company:Sangamo_Therapeutics&oldid=4316310"